Ambrx Biopharma is the top mid-cap pick, is the biggest gainer listed on the Dow Jones Industrial Average, while Ambrx is the tech-heavy Nasdaq’s big winner.Year to date, the S&P, Dow and Nasdaq are up 16%, 4% and 33%, respectively, rebounding from the stock market’s dreadful 2022, which saw the worst returns in 13 years.
Despite the market's headline gains, it’s been far from a banner year for all firms. The median stock listed on the S&P has returned 5%, meaning a few surging names are leading the overall rally. In fact, the weight of the S&P’s two largest components, Apple and Microsoft, is at its highest level in four decades.
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
Best Stocks Of 2023’s First Half: Nvidia Leads Big Tech RenaissanceCompanies powering the generative AI rush are the top returners for all three major stock indexes this year.
อ่านเพิ่มเติม »
24 'strong-buy' stocks with most upside, including one with 340%: TipRanks24 'strong-buy' stocks with the highest potential upsides based on consensus price targets from Wall Street's top-performing analysts, according to a fintech company
อ่านเพิ่มเติม »
Investors Spurn Dividend-Paying Stocks as AI BoomsThe shares have suffered their worst first-half performance relative to nonpayers since 2009.
อ่านเพิ่มเติม »
Wall Street analysts think these 5 bank stocks will do well in the second halfThis quintet of bank stocks may be poised for a strong second half of the year.
อ่านเพิ่มเติม »